SCHEMBL8352128

SCHEMBL8352128

Cc1ccc(-c2cc3cc(Cl)ccc3s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.53
ESR2 Q92731 2/20 0.53
HDAC6 Q9UBN7 4/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
APP P05067 2/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSP90AB1 P08238 1/20 0.38
CYP2A6 P11509 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3621380 0.81 ESR1 (0.68) ESR1ESR2HDAC6HDAC3HDAC1
Trimethylammonium SCHEMBL11531919 0.80 ESR1 (0.45) ESR1ESR2HDAC6HDAC3HDAC1
SCHEMBL26040038 0.80 ESR1 (0.66) ESR1ESR2HDAC6HDAC3HDAC1
SCHEMBL26325133 0.80 ESR1 (0.66) ESR1ESR2HDAC6HDAC3HDAC1
SCHEMBL5685539 0.79 ESR1 (0.61) ESR1ESR2HDAC6HDAC3HDAC1
SCHEMBL28231906 0.79 APP (0.57) ESR1ESR2HDAC6HDAC3HDAC1
Trimethylammonium SCHEMBL11529092 0.79 ESR1 (0.44) ESR1ESR2HDAC6HDAC3HDAC1
SCHEMBL8338272 0.77 APP (0.68) ESR1ESR2HDAC2APPALDH1A1
SCHEMBL18003153 0.76 CYP2A6 (0.40) ESR1ESR2HDAC6HDAC3HDAC1
SCHEMBL19333541 0.75 ESR1 (0.60) ESR1ESR2HDAC6HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999032112-A1 METHOD FOR TREATING DIABETES ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed